1. Psoriasis

Category Archives: Psoriasis

Psoriasis Symptoms, Causes, Treatment – What is psoriasis …

Posted on by

Psoriasis PUVA Treatment Can Increase Melanoma Risk

PUVA (psoralen and ultraviolet A radiation) treatment has been used for decades to treat severe psoriasis. In this "combination" therapy, the psoralen, taken internally, acts as a skin sensitizer. The "sensitized" skin affected by psoriasis can then be treated by ultraviolet A radiation.

Psoriasis is a noncontagious skin condition that produces red papules that merge together into plaques of thickened, scaling skin. The dry flakes of skin scales are thought to result from the excessively rapid proliferation of skin cells that is triggered by abnormal lymphocytes. Psoriasis commonly affects the skin of the elbows, knees, and scalp.

Some people have such mild psoriasis (small, faint dry skin patches) that they may not even suspect that they have a medical skin condition. Others have very severe psoriasis where virtually their entire body is fully covered with thick, red, scaly skin.

Psoriasis is considered an incurable, long-term (chronic) skin condition. It has a variable course, periodically improving and worsening. It is not unusual for psoriasis to spontaneously clear for years and stay in remission. Many people note a worsening of their symptoms in the colder winter months.

Psoriasis affects all races and both sexes. Although psoriasis can be seen in people of any age, from babies to seniors, most commonly patients are first diagnosed in their early adult years. The quality of life of patients with psoriasis is often diminished because of the appearance of their skin. Recently, it has become clear that people with psoriasis are more likely to have diabetes, high blood lipids, and heart disease. There are speculations as to how this might relate to their joint and skin inflammation. Caring for psoriasis takes medical teamwork.

Reviewed on 5/16/2013

Psoriasis Related Articles

Villaseor-Park, Jennifer, David Wheeler, and Lisa Grandinetti. "Psoriasis: Evolving Treatment for a Complex Disease." Cleveland Clinic Journal of Medicine 79.6 June 2012: 413-423.

IMAGES:

Continued here:

Psoriasis Symptoms, Causes, Treatment - What is psoriasis ...

Psoriasis – 100% Natural Treatment Shivax®

Posted on by

Psoriasis is a disease that concerns many people of the world.

Usually we can define Psoriasis as an hereditary illness; in fact it is possible to find different people suffering from this pathology within the same family. Very often in the same family you can find many people suffering from different pathologies as follows: adult diabetes, rheumatoid arthritis, systemic lupus erythematic, vitiligo and psoriasis, too. The reason stands in the Polygenic nature of these diseases. In other words, the trend to fall ill is written, not on a single gene, but on more genes.

The DNA (genetic code) reveals the predisposition of suffering from Psoriasis, even from the birth.

The characteristic Skin lesions will appear only when a person is in a stress condition. This means that there are too many toxins in the body.

A little example...

In a car we have an instrument cluster, full of lights. They can blink to indicate that something doesn't work. In the "human machine" these lightsare represented by different symptoms. The Psoriasis lesions are warning lights that come out to warn us that there are too many toxins in our body.

But where do they come from ?

Link:

Psoriasis - 100% Natural Treatment Shivax®

What Is Psoriasis?

Posted on by

What is Psoriasis?

Psoriasis (sore-EYE-ah-sis) is a medical condition that occurs when skin cells grow too quickly. Faulty signals in the immune system cause new skin cells to form in days rather than weeks. The body does not shed these excess skin cells, so the cells pile up on the surface of the skin and lesions form.

What are the signs and symptoms? The lesions vary in appearance with the type of psoriasis. There are five types of psoriasis: Plaque, guttate, pustular, inverse, and erythrodermic. About 80% of people living with psoriasis have plaque (plak) psoriasis, also called psoriasis vulgaris. Plaque psoriasis causes patches of thick, scaly skin that may be white, silvery, or red. Called plaques (plax), these patches can develop anywhere on the skin. The most common areas to find plaques are the elbows, knees, lower back, and scalp.

Psoriasis also can affect the nails. About 50% of people who develop psoriasis see changes in their fingernails and/or toenails. If the nails begin to pull away from the nail bed or develop pitting, ridges, or a yellowish-orange color, this could be a sign of psoriatic (sore-EE-at-ic) arthritis. Without treatment, psoriatic arthritis can progress and become debilitating. It is important to see a dermatologist if nail changes begin or joint pain develops. Early treatment can prevent joint deterioration.

What causes psoriasis? Psoriasis is not contagious. You cannot get psoriasis from touching someone who has psoriasis, swimming in the same pool, or even intimate contact. Psoriasis is much more complex.

So complex, in fact, scientists are still studying what happens when psoriasis develops. We know that the persons immune system and genes play key roles. In studying the immune system, scientists discovered that when a person has psoriasis, the T cells (a type of white blood cell that fights unwanted invaders such as bacteria and viruses) mistakenly trigger a reaction in the skin cells. This is why you may hear psoriasis referred to as a T cell-mediated disease.

This reaction activates a series of events, causing new skin cells to form in days rather than weeks. The reason T cells trigger this reaction seems to lie in our DNA. People who develop psoriasis inherit genes that cause psoriasis. Unlike some autoimmune conditions, it appears that many genes are involved in psoriasis.

Scientists are still trying to identify all of the genes involved. One of the genes that has been identified is called PSORS1 (SORE-ESS-1). This is one of several genes that regulates how the immune system fights infection.

Scientists also have learned that not everyone who inherits genes for psoriasis gets psoriasis. For psoriasis to appear, it seems that a person must inherit the right mix of genes and be exposed to a trigger. Some common triggers are a stressful life event, skin injury, and having strep throat. Many people say that that their psoriasis first appeared after experiencing one of these. Triggers are not universal. What triggers psoriasis in one person may not cause psoriasis to develop in another.

Who gets psoriasis? People worldwide develop psoriasis. In the United States, nearly 7.5 million people have psoriasis and about 150,000 new cases are diagnosed each year. Studies indicate that psoriasis develops about equally in males and females. Research also shows that Caucasians develop psoriasis more frequently than other races. A study conducted in the United States found the prevalence was 2.5% in Caucasians and 1.3% in African Americans.

See the article here:

What Is Psoriasis?

Sandoz begins Phase III clinical trial for biosimilar adalimumab

Posted on by

Novartis International AG / Sandoz begins Phase III clinical trial for biosimilar adalimumab . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Holzkirchen, Germany, December 19, 2013 - Sandoz, the global leader in biosimilars, announced it has initiated a Phase III clinical trial with its biosimilar version of adalimumab (AbbVie's HUMIRA) - the leading treatment of several autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn's disease. This is Sandoz's eighth Phase III trial initiation across six compounds.

The aim of the study is to demonstrate equivalent efficacy, similarity, and immunogenicity of the Sandoz product versus HUMIRA in patients with moderate to severe plaque-type psoriasis. Sandoz is working closely with physicians and patients on this global trial, which spans 12 countries across Europe, the United States and Asia including Japan.

Psoriasis affects approximately 3% of the world's population[1]. There is significant unmet need in psoriasis with between nine and 30 percent of patients with severe psoriasis receiving no treatment at all[2]. "Because psoriasis is a chronic condition that often requires lifelong management, treatment can become a significant financial strain for many patients and healthcare systems," said Professor Dr. Peter van de Kerkhof, Chairman of the Department of Dermatology at the Radboud University Nijmegen Medical Centre in The Netherlands and President of the International Psoriasis Council (IPC) Board of Directors. "A high-quality and clinically proven biosimilar version of adalimumab could play a meaningful role in alleviating cost burdens related to this disease."

"This latest advancement in our pipeline represents our unwavering commitment to expanding patient access to biologics - particularly in disease areas where there is a significant need for more treatment choices," said Mark McCamish, M.D., Ph.D., and Head of Global Biopharmaceutical & Oncology Injectables Development at Sandoz. "We look forward to bringing a high-quality and affordable biosimilar version of adalimumab to individuals around the world living with psoriasis and other debilitating autoimmune diseases such as rheumatoid arthritis."

"Adalimumab will be a key building block in our growing Immunology portfolio, which includes other biosimilar candidates currently in Phase III trials such as etanercept (Amgen's Enbrel) and rituximab (Roche's Rituxan/MabThera)," said Ameet Mallik, Sandoz' Head of Biopharmaceuticals and Oncology Injectables. "This key development milestone further strengthens our global leadership in biosimilars and builds on our industry-leading pipeline."

Sandoz is the pioneer in biosimilars and the global market leader with over 50 percent market segment share of all biosimilars approved in the highly regulated markets of U.S., Canada, Europe, Japan and Australia. All three Sandoz biosimilars occupy the #1 biosimilar position (volume market share) in their respective categories. Sandoz biosimilars are sold in over 50 countries and have generated over 100 million patient exposure days in experience.

Disclaimer This press release contains forward-looking statements that can be identified by terminology such as "begins," "will," "aim," "can," "could," "commitment," "look forward to," "growing," or similar expressions, or by express or implied discussions regarding potential new biosimilar products; or regarding potential future sales of biosimilar products. Such forward-looking statements reflect the current views of the Novartis Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new biosimilar products will be submitted or approved for sale in any market. Nor can there be any guarantee that Sandoz will achieve any particular financial results from its biosimilar products. In particular, management's expectations could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, including the potential outcome of the FDA's biosimilars regulatory process; unexpected clinical trial results, including additional analyses of existing clinical data or unexpected new clinical data; unexpected product manufacturing issues; government, industry, and general public pricing pressures; competition in general; unexpected development difficulties; unexpected patent litigation outcomes; the impact that the foregoing factors could have on the values attributed to the Group's assets and liabilities as recorded in the Group's consolidated balance sheet; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

About Sandoz

Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the rapidly growing generics industry. Sandoz employs over 26,000 employees in more than 140 countries, offering broad range of over 1,000 high-quality, affordable products that are no longer protected by patents. With USD 8.7 billion in sales in 2012, Sandoz holds the #1 position globally in biosimilars as well as generic injectables, ophthalmics, dermatology and antibiotics as well as strong positions in the treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments, and hormone therapies. Sandoz develops, produces, and markets these medicines along with pharmaceutical and biotechnological active substances. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003 , Sandoz has benefitted from strong growth of its acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).

Follow this link:

Sandoz begins Phase III clinical trial for biosimilar adalimumab

Psoriasis – Wikipedia, la enciclopedia libre

Posted on by

La psoriasis (AFI:[soja.sis], del griego , picor) es una enfermedad inflamatoria crnica de la piel que produce lesiones escamosas engrosadas e inflamadas, con una amplia variabilidad clnica y evolutiva. No es contagiosa, aunque s puede ser hereditaria, es ms probable que la hereden los hombres que las mujeres.

Puede afectar a cualquier parte de la piel, frecuentemente a las zonas de codos, rodillas, cuero cabelludo, abdomen y espalda. No es raro que produzca afectacin de las uas.Esto se conoce como psoriasis ungueal. Las uas pueden ser la nica zona afectada al principio de la psoriasis. En ocasiones produce complicaciones como la artritis psorisica.

La clasificacin ms utilizada se organiza segn los sntomas, los tipos de lesiones cutneas y la gravedad general del cuadro. Es la clasificacin ms til para la eleccin de su tratamiento y para el conocimiento del pronstico de la enfermedad en cada paciente. La clasificacin est detallada en el apartado de manifestaciones clnicas. En la antigedad era falsamente diagnosticada como lepra, debido a la similitud de sintomatologa.

Se estima que entre un 1 y un 3% de la poblacin sufre de psoriasis.[1][2] Si bien puede aparecer a cualquier edad, suele hacerlo entre los 15 y los 35 aos, con un pico mximo de incidencia en la segunda dcada. Afecta por igual a ambos sexos, aunque es ms precoz en mujeres y en personas con antecedentes familiares. Por otro lado, no existe relacin entre psoriasis y cncer de piel (no maligniza).

La causa de la psoriasis es una velocidad anormalmente alta de mitosis en las clulas epidrmicas que se puede relacionar con una sustancia transportada en la sangre, un defecto en el sistema inmune.

Se cree que no tiene una causa nica, sino multifactorial, en individuos con predisposicin gentica a padecerla y que puede ser desencadenada o exacerbada por diversos factores ambientales.

La herencia de esta enfermedad es posiblemente polignica. Se ha demostrado una importante agregacin familiar,[3] el aumento de concordancia en gemelos monocigotos y la asociacin a determinados HLA.

En este sentido, se asocia la predisposicin a psoriasis con los antgenos HLA-CW6, y HLA-DR7. Adems, existe correlacin entre el tipo clnico de psoriasis y otros antgenos HLA. Por ejemplo, el HLA-B17 se asocia a un inicio ms precoz y un curso ms grave, y el HLA-B27 est relacionado con la forma pustulosa generalizada.

Entre otros, cabe destacar:

Aunque est poco esclarecida, hay dos hechos bsicos: la hiperplasia epidrmica por un aumento de la poblacin germinativa, y el infiltrado inflamatorio de la dermis. La inflamacin viene mediada por el Linfocito T CD4+ que libera (junto al queratinocito) citocinas proliferativas, que estimulan la proliferacin de las clulas epidrmicas. La respuesta inflamatoria es de tipo celular, frente a un autoantgeno an desconocido, o frente a un superantgeno estreptoccico en el caso de la psoriasis en gotas postinfecciosa.

Link:

Psoriasis - Wikipedia, la enciclopedia libre

Psoriasis Symptoms, Treatment, Causes, Medication Information …

Posted on by

Psoriasis facts Psoriasis is a chronic inflammatory skin disease. Patients with psoriasis who are obese are predisposed to diabetes and heart disease. Psoriasis can be initiated by certain environmental triggers. A predisposition for psoriasis is inherited in genes. Psoriasis is not contagious. Psoriasis gets better and worse spontaneously and can have periodic remissions (clear skin). Psoriasis is controllable with medication. Psoriasis is currently not curable. There are many promising therapies, including newer biologic drugs. Future research for psoriasis is promising. What is psoriasis?

Psoriasis is a noncontagious skin condition that produces red papules that merge together into plaques of thickened, scaling skin. The dry flakes of skin scales are thought to result from the excessively rapid proliferation of skin cells that is triggered by abnormal lymphocytes. Psoriasis commonly affects the skin of the elbows, knees, and scalp.

Some people have such mild psoriasis (small, faint dry skin patches) that they may not even suspect that they have a medical skin condition. Others have very severe psoriasis where virtually their entire body is fully covered with thick, red, scaly skin.

Psoriasis is considered an incurable, long-term (chronic) skin condition. It has a variable course, periodically improving and worsening. It is not unusual for psoriasis to spontaneously clear for years and stay in remission. Many people note a worsening of their symptoms in the colder winter months.

Psoriasis affects all races and both sexes. Although psoriasis can be seen in people of any age, from babies to seniors, most commonly patients are first diagnosed in their early adult years. The quality of life of patients with psoriasis is often diminished because of the appearance of their skin. Recently, it has become clear that people with psoriasis are more likely to have diabetes, high blood lipids, and heart disease. There are speculations as to how this might relate to their joint and skin inflammation. Caring for psoriasis takes medical teamwork.

Medically Reviewed by a Doctor on 5/16/2013

Psoriasis - Effective Treatments Question: What kinds of treatments have been effective for your psoriasis?

Psoriasis - Symptoms Question: What symptoms and signs did you experience with psoriasis?

Scalp Psoriasis - Creams and Lotions Question: Which creams or lotions (topical medications) have helped you treat scalp psoriasis?

Medical Author:

More here:

Psoriasis Symptoms, Treatment, Causes, Medication Information ...


  1. Psoriasis